美国安进地舒单抗注射液的适应症

Indications for Amgen Injection in the United States: Desosumab Xgeva is indicated for the prevention of bone-related events in patients with bone metastases from solid tumors. Important limitations to the use of denosumab Xgeva: It is not indicated for the prevention of bone-related events in patients with multiple myeloma.

Desosumab Xgeva is produced by Amgen in the United States. Amgen is the world's leading innovative biopharmaceutical R&D and manufacturing company. It takes "drug innovation" as its core concept and attaches great importance to the accumulation of R&D capabilities. It has achieved major breakthroughs in the fields of human genome, tumor biology, neuroscience, hematology and other fields.

Desosumab Xgeva is easy to use and can be injected subcutaneously by the patient at 60 mg/time with an interval of 6 months. While being treated with denosumab Xgeva, patients need to take 1000mg of calcium and at least 4001U of vitamin D per day. While patients are receiving denosumab Xgeva treatment, they should not increase or decrease the dose of the drug without authorization. Only correct use of the drug will help the condition.

It is worth noting that unlike bisphosphonates, which maintain long-term effects, denosumab Xgeva does not bind to its receptors for long-term retention. Reports have shown that the effect of denosumab Xgeva on increasing bone density and improving bone turnover indicators is reversible. When drug use is discontinued, acute bone loss will bring about the risk of multiple vertebral fractures. Patients should be aware of this.

Treatment with denosumab Xgeva may lead to hypocalcemia. Although the overall incidence of hypocalcemia during the use of denosumab Xgeva is low, patients with renal insufficiency should monitor and correct blood calcium levels before and after starting denosumab Xgeva treatment, and may add calcium and vitamin D as a preventive measure.

The above is the introduction to Xgeva. If patients have other questions about denosumab Xgeva (such as drug prices, purchase channels, etc.), they can consult the medical companion travel service.

Recommended related hot articles: /newsDetail/91003.html